Bellevue Group AG — 13F Holdings & Portfolio
CIK 1674546 · latest 13F-HR filed 2026-05-15
Bellevue Group AG manages $4.20B in 13F-reported U.S. long-equity assets across 167 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are VRTX (7.09%), ARGX (5.44%), REGN (5.10%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 19 new positions, exited 40, added to 30, and trimmed 95.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$4.20B
Long-equity book
167
Distinct positions
2026-03-31
Filed 2026-05-15
+19 / −40 / ↑30 / ↓95
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- REGENERON PHARMACEUTICALS$204.6M +1902.8%
- GILEAD SCIENCES INC$156.6M +2418.2%
- CRINETICS PHARMACEUTICALS IN$118.9M +63245.9%
- AMGEN INC$97.9M +1617.3%
- ULTRAGENYX PHARMACEUTICAL IN$49.8M +83926.0%
Top Trims
- REVOLUTION MEDICINES INC-$248.5M -62.3%
- IONIS PHARMACEUTICALS INC-$243.3M -64.1%
- NEUROCRINE BIOSCIENCES INC-$241.0M -99.7%
- ARGENX SE-$159.8M -41.2%
- ALNYLAM PHARMACEUTICALS INC-$99.7M -56.2%
New Positions
- ENLIVEN THERAPEUTICS INC$91.0M
- VAXCYTE INC$69.2M
- DAMORA THERAPEUTICS INC$59.5M
- DISC MEDICINE INC$29.4M
- ORUKA THERAPEUTICS INC$24.9M
Exited Positions
- AVIDITY BIOSCIENCES INC$189.8M
- AMICUS THERAPEUTICS INC$152.9M
- MAZE THERAPEUTICS INC$36.8M
- CAREDX INC$8.1M
- MOLINA HEALTHCARE INC$8.1M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | VERTEX PHARMACEUTICALS INC | VRTX | 92532F100 | $298.0M | 7.09% | 667,375 | SH |
| 2 | ARGENX SE | ARGX | 04016X101 | $228.6M | 5.44% | 313,000 | SH |
| 3 | REGENERON PHARMACEUTICALS | REGN | 75886F107 | $214.1M | 5.10% | 277,132 | SH |
| 4 | SCHOLAR ROCK HLDG CORP | SRRK | 80706P103 | $176.0M | 4.19% | 3,579,278 | SH |
| 5 | GILEAD SCIENCES INC | GILD | 375558103 | $155.8M | 3.71% | 1,118,000 | SH |
| 6 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $149.8M | 3.57% | 1,540,588 | SH |
| 7 | IONIS PHARMACEUTICALS INC | IONS | 462222100 | $134.4M | 3.20% | 1,790,000 | SH |
| 8 | INTUITIVE SURGICAL INC | ISRG | 46120E602 | $132.1M | 3.14% | 286,654 | SH |
| 9 | VIRIDIAN THERAPEUTICS INC | VRDN | 92790C104 | $131.4M | 3.13% | 6,717,515 | SH |
| 10 | KRYSTAL BIOTECH INC | KRYS | 501147102 | $124.1M | 2.95% | 480,322 | SH |
| 11 | CRINETICS PHARMACEUTICALS IN | CRNX | 22663K107 | $119.1M | 2.84% | 3,280,000 | SH |
| 12 | ABBOTT LABORATORIES | ABT | 002824100 | $118.2M | 2.81% | 1,151,635 | SH |
| 13 | NUVALENT INC | NUVL | 670703107 | $107.9M | 2.57% | 1,053,268 | SH |
| 14 | AMGEN INC | AMGN | 031162100 | $94.3M | 2.24% | 268,000 | SH |
| 15 | BOSTON SCIENTIFIC CORP | BSX | 101137107 | $92.0M | 2.19% | 1,466,894 | SH |
| 16 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $91.0M | 2.17% | 2,320,867 | SH |
| 17 | IMMUNOCORE HLDGS PLC | IMCR | 45258D105 | $84.3M | 2.01% | 2,796,803 | SH |
| 18 | MEDTRONIC PLC | MDT | G5960L103 | $83.0M | 1.97% | 957,329 | SH |
| 19 | RELAY THERAPEUTICS INC | RLAY | 75943R102 | $77.5M | 1.85% | 7,793,318 | SH |
| 20 | ALNYLAM PHARMACEUTICALS INC | ALNY | 02043Q107 | $77.3M | 1.84% | 233,679 | SH |
| 21 | STRYKER CORPORATION | SYK | 863667101 | $71.4M | 1.70% | 217,237 | SH |
| 22 | VAXCYTE INC | PCVX | 92243G108 | $69.2M | 1.65% | 1,190,697 | SH |
| 23 | VERA THERAPEUTICS INC | VERA | 92337R101 | $68.1M | 1.62% | 1,692,906 | SH |
| 24 | EDWARDS LIFESCIENCES CORP | EW | 28176E108 | $67.2M | 1.60% | 839,451 | SH |
| 25 | DAMORA THERAPEUTICS INC | DMRA | 36322Q206 | $59.5M | 1.42% | 2,298,000 | SH |
| 26 | TANGO THERAPEUTICS INC | TNGX | 87583X109 | $50.2M | 1.19% | 2,400,000 | SH |
| 27 | IDEXX LABS INC | IDXX | 45168D104 | $50.1M | 1.19% | 89,131 | SH |
| 28 | ULTRAGENYX PHARMACEUTICAL IN | RARE | 90400D108 | $49.9M | 1.19% | 2,380,000 | SH |
| 29 | DEXCOM INC | DXCM | 252131107 | $49.5M | 1.18% | 788,766 | SH |
| 30 | JADE BIOSCIENCES INC | JBIO | 008064206 | $49.2M | 1.17% | 3,501,502 | SH |
| 31 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $48.1M | 1.15% | 1,528,518 | SH |
| 32 | UNITEDHEALTH GROUP INC | UNH | 91324P102 | $40.1M | 0.95% | 148,203 | SH |
| 33 | DANAHER CORP DEL | DHR | 235851102 | $38.3M | 0.91% | 202,164 | SH |
| 34 | CELLDEX THERAPEUTICS INC NEW | CLDX | 15117B202 | $38.1M | 0.91% | 1,200,000 | SH |
| 35 | RESMED INC | RMD | 761152107 | $35.8M | 0.85% | 159,346 | SH |
| 36 | INSULET CORP | PODD | 45784P101 | $34.3M | 0.82% | 163,656 | SH |
| 37 | THERMO FISHER SCIENTIFIC INC | TMO | 883556102 | $31.7M | 0.75% | 64,412 | SH |
| 38 | ELI LILLY & CO | LLY | 532457108 | $31.2M | 0.74% | 33,932 | SH |
| 39 | GE HEALTHCARE TECHNOLOGIES I | GEHC | 36266G107 | $29.7M | 0.71% | 416,887 | SH |
| 40 | DISC MEDICINE INC | IRON | 254604101 | $29.4M | 0.70% | 459,314 | SH |
| 41 | JOHNSON & JOHNSON | JNJ | 478160104 | $29.1M | 0.69% | 119,102 | SH |
| 42 | ANNEXON INC | ANNX | 03589W102 | $28.6M | 0.68% | 5,157,290 | SH |
| 43 | THE CIGNA GROUP | CI | 125523100 | $26.2M | 0.62% | 98,263 | SH |
| 44 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $24.9M | 0.59% | 507,008 | SH |
| 45 | MERCK & CO INC | MRK | 58933Y105 | $24.9M | 0.59% | 206,591 | SH |
| 46 | ALIGN TECHNOLOGY INC | ALGN | 016255101 | $23.9M | 0.57% | 139,680 | SH |
| 47 | STERIS PLC | STE | G8473T100 | $22.1M | 0.53% | 99,878 | SH |
| 48 | GLOBUS MED INC | GMED | 379577208 | $21.3M | 0.51% | 247,261 | SH |
| 49 | MONTE ROSA THERAPEUTICS INC | GLUE | 61225M102 | $20.6M | 0.49% | 1,250,000 | SH |
| 50 | ABBVIE INC | ABBV | 00287Y109 | $20.3M | 0.48% | 93,567 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $4.20B | 167 | 0001104659-26-061375 |
| 2025-12-31 | 2026-02-17 | $5.28B | 213 | 0001104659-26-016360 |
| 2025-09-30 | 2025-11-14 | $4.81B | 186 | 0001104659-25-112697 |